USD 11.73
(-4.71%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -2.50 USD | -1566.67% |
2022 | -0.15 USD | 84.54% |
2021 | -0.97 USD | 23.62% |
2020 | -1.27 USD | -805.56% |
2019 | 0.18 USD | -35.71% |
2018 | 0.28 USD | 132.18% |
2017 | -0.87 USD | -569.23% |
2016 | -0.13 USD | 77.97% |
2015 | -0.59 USD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | 0.06 USD | 120.69% |
2024 Q2 | -0.10 USD | -266.67% |
2023 Q2 | -0.20 USD | -195.24% |
2023 Q4 | -0.29 USD | 86.94% |
2023 FY | - USD | -1566.67% |
2023 Q3 | -2.22 USD | -1010.0% |
2023 Q1 | 0.21 USD | 290.91% |
2022 Q4 | -0.11 USD | -10.0% |
2022 FY | - USD | 84.54% |
2022 Q3 | -0.10 USD | -122.22% |
2022 Q2 | -0.04 USD | -145.0% |
2022 Q1 | 0.10 USD | 150.0% |
2021 Q3 | -0.21 USD | 51.16% |
2021 FY | - USD | 23.62% |
2021 Q4 | -0.20 USD | 4.76% |
2021 Q1 | -0.13 USD | 80.3% |
2021 Q2 | -0.43 USD | -230.77% |
2020 Q3 | -0.29 USD | -123.08% |
2020 Q4 | -0.66 USD | -127.59% |
2020 FY | - USD | -805.56% |
2020 Q1 | -0.12 USD | -370.59% |
2020 Q2 | -0.13 USD | -8.33% |
2019 Q4 | -0.03 USD | -185.0% |
2019 Q3 | 0.03 USD | -70.0% |
2019 Q2 | 0.10 USD | 11.11% |
2019 FY | - USD | -35.71% |
2019 Q1 | 0.09 USD | 125.0% |
2018 Q4 | 0.04 USD | -75.0% |
2018 FY | - USD | 132.18% |
2018 Q3 | 0.16 USD | 188.89% |
2018 Q2 | -0.18 USD | -190.0% |
2018 Q1 | 0.20 USD | 144.44% |
2017 Q1 | - USD | 0.0% |
2017 Q4 | -0.45 USD | -695.05% |
2017 Q2 | - USD | 0.0% |
2017 Q3 | -0.06 USD | 0.0% |
2017 FY | - USD | -569.23% |
2016 FY | - USD | 77.97% |
2015 FY | - USD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Amneal Pharmaceuticals, Inc. | -0.48 USD | -420.833% |
Bausch Health Companies Inc. | -1.62 USD | -54.321% |
Catalent, Inc. | -5.76 USD | 56.597% |
Emergent BioSolutions Inc. | -14.85 USD | 83.165% |
Perrigo Company plc | -0.09 USD | -2562.407% |
Teva Pharmaceutical Industries Limited | -0.50 USD | -400.0% |
Zoetis Inc. | 5.08 USD | 149.213% |